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Abstract: Background: Ovaries are sensitive to chemotherapy, which may lead to early depletion of 
primordial follicle reserve. One strategy for gonadal function preservation is temporary ovarian 
suppression with Gonadotropin Releasing Hormone agonists (GnRHa) during chemotherapy. To 
date, GnRHa protective mechanism of action remains not fully elucidated. Methods: We collected 
260 immature cumulus cell-oocyte complexes (COC) from 111 women < 38 years old, with a normal 
ovarian reserve. The COC were randomly assigned to the following groups: a) control; culture with 
the addition of b) GnRHa; c) cyclophosphamide; d) cyclophosphamide plus GnRHa. After in vitro 
treatments, RNA and proteins were extracted from oocytes and cumulus cells (CC), separately. 
Potential effects of drugs were evaluated on GnRH receptors, apoptosis pathways, ceramide 
pathway, and glutathione synthesis by quantitative PCR and, whenever possible, by Western blot. 
Results: Cyclophosphamide triggered activation of the extrinsic pathway of apoptosis mediated by 
BAX in CC. The co-administration of GnRHa inhibited the apoptosis pathway in CC. According to 
our model, the GnRHa does not directly act on oocytes, which do not express GnRH receptors. 
Moreover, glutathione synthesis was decreased after GnRHa treatment both in CC and oocytes. 
Conclusion: Our data suggest that the protective mechanisms induced by GnRHa is mediated by an 
anti-apoptotic effect on CC. 




Young women with cancer or non-malignant diseases requiring treatment with cytotoxic 
chemotherapy are candidates for fertility preservation. The ovarian reserve is constituted by a fixed 
number of resting primordial follicles present at birth that are slowly depleted throughout a woman’s 
reproductive life [1]. The ovaries are very sensitive to cytotoxic chemotherapy agents; they can induce 
apoptotic death of the oocytes and the surrounding granulosa cells (GC), leading to irreversible early 
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depletion of the primordial follicle reserve [2–4]. Therefore, in young females, chemotherapy can 
induce premature ovarian insufficiency and infertility [5].  
Strategies for preservation of female gonadal function and/or fertility include temporary ovarian 
suppression with Gonadotropin Releasing Hormone agonists (GnRHa), oocyte/embryo or ovarian 
tissue cryopreservation [6,7]. In comparison with cryopreservation strategies, temporary ovarian 
suppression with GnRHa during chemotherapy has been developed specifically, as a technique to 
protect the ovaries from the gonadotoxic effect of cytotoxic systemic therapy. In addition, the main 
advantages are that it is simple to administer, less invasive and expensive, and does not require delay 
in initiating anticancer therapies. Important novel research efforts in the field have elucidated the 
efficacy and safety of this option, and it is now endorsed for clinical use by several guidelines [6–9]. 
Nevertheless, the performance of this strategy remains still debated [10]. Firstly, while consistent data 
proved the efficacy of the use of temporary ovarian suppression with GnRHa during chemotherapy 
in breast cancer patients [11], negative results were obtained in trials conducted in women with 
tumors other than breast cancer (i.e., hematological malignancies) [12,13]. Secondly, in terms of 
fertility preservation potential of GnRHa use during chemotherapy, available data are limited. The 
most recent meta-analyses have shown a significantly higher post-treatment pregnancy rate for 
premenopausal breast cancer patients treated with GnRHa during chemotherapy, as compared to 
those treated with cytotoxic therapy alone [8,9,11,13–16], without benefit in lymphoma patients 
[12,13]. Thirdly, concerning experimental preclinical data, the potential mechanisms of action for the 
protective effects of GnRHa during chemotherapy remains not fully clarified. Several experimental 
studies have been conducted in both female mice and rats. The majority of the studies showed a 
positive effect for GnRHa treatment in preventing chemotherapy-induced depletion of primordial 
follicles [17–25]. However, other studies did not confirm these findings [26–29]. Importantly, very 
limited experimental preclinical data are available in female primates and human models [30–32].  
In regard to the activated pathway, stimulation of mouse granulosa cells with GnRHa did not 
induce a detectable rise in cAMP levels [27,33]. However, a recent study reported increased cAMP 
levels in human cortical pieces and in granulosa cell lines following GnRHa stimulation [32], thus 
suggesting potential different actions of GnRHa in rodents and humans. Therefore, further 
investigation in human models are needed because of crucial importance considering the already 
available clinical use for this strategy. 
Hereby, we studied immature cell-oocyte complexes (COC) discarded from in vitro fertilization 
cycles in healthy women to investigate whether GnRHa was able to protect the oocytes from 
cyclophosphamide toxicity. Although chemotherapy damages primordial follicle oocytes, this was 
the only strategy available to us for treatment of ex vivo human COC, the major anatomic and 
functional unit of the ovary. The COC were cultured without the addition of drugs, in the presence 
of cyclophosphamide alone or GnRHa alone or both drugs. Effects of these treatments were evaluated 
on GnRH receptors, apoptosis pathways, ceramide pathway, and glutathione synthesis. Data were 
collected on both oocytes and cumulus cells (CC) by gene expression analysis. 
2. Results 
2.1. GnRH Receptors 
In CC, only the GnRHR-I gene was detectable and its expression level was not modulated by 
treatment. In the oocytes, neither GnRHR-I nor GnRHR-II genes were expressed or induced by 
chemotherapy and GnRHa. 
2.2. Apoptosis Pathway 
In CC, BAK1, BCL2L10, FASL, and TP63 pro-apoptotic genes were not expressed. Figure 1 shows 
expression profiles of the expressed pro-apoptotic genes in CC.  
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Figure 1. Expression levels of BAX, CASP3, CD40, FAS, TP53, TNFα, TRAIL, TRAF3 pro-apoptotic 
genes in CC of cell-oocyte complexes (COC) cultured without the addition of drugs (control, C), 
treated with GnRHa (A), phosphoramide mustard (P), and GnRHa+phosphoramide mustard (A+P). 
Results are expressed as log2(2-ddCq) values using HPRT1 as reference gene and C group as calibrator. 
Error bars denote standard error. *: p value < 0.05 in P and A+P versus A group. 
The expression of TP53 was not modified by any treatment. Expression levels of BAX, CASP3, 
FAS, and TRAF3 were increased in P group as compared to C group and they were diminished after 
GnRHa treatment. Such a behavior was particularly evident for BAX and FAS genes, that, compared 
to A group, were significantly up-regulated both in P (p = 0.0152 and p = 0.0006, respectively) and in 
A+P group (p = 0.0015 and p = 0.0006, respectively). A trend of decreasing expression of BAX and FAS 
was observed in A+P group than in the P one. Western Blotting analysis of BAX showed the presence 
of BAX~21KDa (putatively BAXα, the most common form of BAX [34]) and BAX~18KDa that could 
be the BAX cleaved product (Figure 2).  
 
Figure 2. Western blot analysis of BAX in CC of COC cultured without the addition of drugs (control 
group, C), treated with GnRHa (A), phosphoramide mustard (P), and GnRHa+phosphoramide 
mustard (A+P). The rabbit polyclonal anti-BAX antibody was diluted 1:1000. 
The expression level of BAX~21 KDa seems to increase in P compared to C and A groups, and 
to diminish in A+P group with respect to P group. Moreover, the ratio between BAX~21 KDa and 
BAX~18 KDa tends to increase following chemotherapy treatment, suggesting that 
cyclophosphamide may promote the synthesis of BAX~21 KDa. Due to the low amount of material 
and the difference in protein loading because of interfering in quantification due to Human Serum 
Albumin (HSA) in IVF medium, these results should only be interpreted qualitatively. 
A trend for increased expression of CD40 and TNFα was observed moving from A to P and A+P 
treatments. A statistically significant reduction of TRAIL expression was observed in the P and A+P 
group, as compared to A group (p = 0.0005 and p = 0.0015, respectively).  
In CC, all anti-apoptotic genes were expressed, with the exception of BIRC5 (Figure 3). 
Expression of BCL2 gene was significantly modified by the different treatments: its expression was 
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reduced in P group (p = 0.0256) and increased in A+P group (p = 0.0087). On the other hand, BAG3 
and TRAF2 expression was increased in P group and slightly diminished in A+P group, without 
reaching statistical significance. Expression of CFLAR was not modified by any treatment. 
 
Figure 3. Expression levels of BCL2, CFLAR, BAG3, and TRAF2 anti-apoptotic genes in CC of COC 
cultured without the addition of drugs (control, C), treated with GnRHa (A), phosphoramide mustard 
(P), and GnRHa+phosphoramide mustard (A+P). Results are expressed as log2 (2-ddCq) values using 
HPRT1, as a reference gene and the C group as a calibrator. Error bars denote standard error. *: p 
value < 0.05 in A group versus P group; #: p value < 0.05 in P group versus A+P group. 
In oocytes, BAK1, CD40, FASL, TNFα, and TRAIL pro-apoptotic genes were not expressed. The 
levels of BAX and BCL2L10 mRNAs were not modified by any treatment. The expression of CASP3, 
TP53, TP63, and TRAF3 was heterogeneously modulated by all the administered drugs 
(Supplementary Figure S1A). FAS gene was not evaluable because of its high variability among the 
replicates. All anti-apoptotic genes were expressed in the oocytes with the exception of BCL2 that was 
detected only in the C group. The expression of BIRC5, CFLAR, BAG3, and TRAF2 was not 
significantly modulated by treatments (Supplementary Figure S1B). 
2.3. Sphingomyelin Pathway 
The CC expressed all sphingomyelin pathway genes, whereas in the oocytes, SPHK1 was not 
detected. The changes in genes of ceramide-sphingosine pathway were not statistically significant 
(Supplementary Figure S2), which unfortunately indicates inadequate quantity of the investigated 
material. 
2.4. Glutathione-Mediated Pathway  
The GCLM gene was expressed in both the CC (Figure 4A) and the oocytes (Figure 4B). Its 
expression was significantly higher in the P group, as compared to the A group in CC and oocytes (p 
= 0.0191 and p = 0.0421, respectively). In the A+P group, a significant reduction of GCLM level was 
observed in both CC (p = 0.0191) and oocytes (p = 0.0171) compared to the P group. 
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Figure 4. (A) Expression levels of GCLM gene in CC of COC cultured without the addition of drugs 
(control, C), treated with GnRHa (A), phosphoramide mustard (P), and GnRHa+phosphoramide 
mustard (A+P); (B) Expression levels of GCLM gene in oocytes of COC cultured without the addition 
of drugs (control, C), treated with GnRHa (A), phosphoramide mustard (P), and 
GnRHa+phosphoramide mustard (A+P). Results are expressed as log2 (2-ddCq) values using HPRT1 as 
reference gene and C group as calibrator. Error bars denote standard error. *: p value < 0.05 in A group 
versus P group; #: p value < 0.05 in P group versus AP group. 
3. Discussion 
To date, the potential protective mechanism of action of temporary ovarian suppression with 
GnRHa during chemotherapy is highly debated and remains not clearly elucidated. Potential 
hypothesized mechanisms include [10,35–37]: i) interruption of Follicle-Stimulating Hormone 
secretion determining a hypo-gonadotropic milieu, in which follicular recruitment is inhibited and 
fewer primordial follicles attain the chemotherapy-sensitive stages of proliferation and follicle 
maturation; ii) decrease in utero-ovarian perfusion due to the hypo-estrogenic state generated by 
pituitary-gonadal desensitization; iii) activation of GnRH receptors; iv) up-regulation of intra-
gonadal anti-apoptotic molecules; or v) protection of undifferentiated germ line stem cells . However, 
so far, none of these hypotheses has been definitively demonstrated. With the exception of three 
reports (one using ex-vivo and in vitro human cells [32] and two a mouse model [26,27]), the majority 
of in vivo [19,20,24,29,30,38–42] and in vitro [29,31,43] studies showed that GnRHa maintains 
primordial follicles and inhibit chemotherapy-induced apoptosis. So far, only three reports on the 
molecular mechanisms of function of GnRHa on cells/tissue of human origin (namely, ovarian cancer 
cells [43], granulosa GC [31], ex vivo and in vitro models of ovary and GC [32]) are available. 
The novelty of our work lies in studying human, ex vivo COC. Indeed, we treated the COC and 
then analyzed the effect of GnRHa and cyclophosphamide in the oocyte and CC compartments, 
separately. Such an experimental set-up allowed us to closely simulate the physiological 
microenvironment, since COC is a fundamental anatomic and functional unit of the ovarian tissue, 
and oocyte growth and competence are dependent on bidirectional communication between the 
oocyte and the CC [44,45]. We adopted a culture system on the bases of experience from IVF. First, 
we used a bicarbonate buffered culture medium designed for the incubation of oocytes, 
supplemented with HSA, gentamicin, antioxidants, non-essential amino acids, and glucose for 
efficient COC survival. Second, COC incubation was performed in a controlled atmosphere with low 
oxygen tension (5%), in order to closely mimic conditions of the natural female environment since in 
the human uterus, the oxygen tension ranges between 2–8% [46]. Such a hypoxic culture reduces the 
generation of reactive oxygen species and related damage to oocytes [47]. 
Our experiments on COC showed that cyclophosphamide was mainly detrimental to the CC 
compartment. In fact, chemotherapy started a series of molecular signals to trigger apoptosis through 
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the extrinsic pathway activation [48]. Specifically, in CC, the cyclophosphamide-mediated death 
signal seemed to be transmitted from the cell surface to the intracellular signaling effectors mainly 
by involvement of FAS, and marginally by CD40, TRAF3 and TNFα, all members of the tumor 
necrosis factor receptor gene superfamily [49]. The CC commitment to apoptosis was mediated by 
the anti-apoptotic BCL2 and the pro-apoptotic BAX genes [50], whose expression was down- and up-
regulated after chemotherapy, respectively. At the protein level, we observed the presence of 
BAX~18KDa that may reflect a cellular stress due to the extended culture. Intriguingly, the trend for 
increased BAX~21 KDa to BAX~18 KDa ratio observed following chemotherapy suggests that 
cyclophosphamide may promote synthesis of BAX~21KDa that in turn, may trigger the activation of 
apoptosis. This effect seems to be partially counteracted by GnRHa.  
Finally, the trend of CASP3 up-regulation in CC treated with cyclophosphamide suggested that 
caspase-3 may be one of the “executioner” caspases activated at the end of the process. The resulting 
cell death was displayed by the morphological changes observed in CC in response to 
cyclophosphamide. 
The administration of GnRHa before cyclophosphamide tended to down-regulate expression of 
pro-apoptotic genes as FAS, TRAF3, BAX, CASP3, and up-regulate transcription of anti-apoptotic 
BCL2 in CC. Our molecular data did not demonstrate a direct GnRHa-mediated protection against 
the cytotoxic effects of cyclophosphamide in the oocytes. In fact, we observed a morphological rescue 
of the oocytes without any significant modulation of the analyzed genes when chemotherapy was 
combined with GnRHa. Taken together, these results suggest that the co-administration of GnRHa 
with chemotherapy inhibited the extrinsic apoptotic signaling pathway in CC only, whereas it did 
not impact on the oocytes. In other words, oocytes may survive the detrimental effect of 
cyclophosphamide thanks to the protective role of the surrounding GC. Moreover, we demonstrated 
at molecular level that GnRHa directly targets the CC, since the GnRHR-I gene was detectable only 
in these cells without any evident modulation by treatments. This finding in our model is in 
agreement with a previous report showing that GnRH receptors are mainly expressed by 
proliferating and luteinized GC of the growing follicles and corpus luteum, respectively [51].  
Finally, the investigation of the first rate-limiting enzyme of glutathione synthesis [52] showed 
that in both CC and oocytes, glutathione synthesis was induced by cyclophosphamide. This is in line 
with prior evidence suggesting that glutathione is an important intracellular antioxidant playing 
several vital roles in the cells such as anti-oxidation and detoxification of xenobiotics [53]. Specifically, 
in the metabolism-dependent toxicity of chemotherapy, the glutathione has a role in binding 
phosphoramide mustard and acrolein, two toxic and highly reactive metabolites. The resulting 
sulfhydryl-containing compounds protect against toxicity of these alkylating agents and at the same 
time do not interfere with the chemotherapeutic activity of cyclophosphamide [54]. Consistently with 
the protective effect of GnRHa, and thus the reduced need of a detoxifying system, we observed a 
decrease of GCLM in CC and in oocytes after GnRHa treatment.  
Although the expression of investigated targets was detected at low levels because of paucity of 
RNAs and proteins due to the nature of our COC model, we hypothesize that GnRHa directly may 
act on CC to protect the oocytes from cyclophosphamide toxicity by an anti-apoptotic effect. It is 
noteworthy that the protective role of GnRHa against cyclophosphamide has been recently excluded 
in ex vivo and in vitro models of human ovary and GC [32]. We believe that the opposite conclusions 
may be due both to the different timing of drugs administration and to the different dose of GnRHa 
used for experiments. In fact, in Bildik’s model, GnRHa was administered to cells at the same time as 
chemotherapy or 1–2 h prior to cyclophosphamide, whereas in A+P group of our model the 
incubation with GnRHa was performed 24 h before the addiction of chemotherapy to COC. Such a 
GnRHa schedule better mimics the protocol used in the clinic with patients starting GnRHa at least 
1 week before chemotherapy initiation [55]. Moreover, in Bildik’s experiments the GnRHa was used 
at 10-20-40 nM, that is two order of magnitude lower than ours (1 µM). Thus, we suggest that prior 
and longer exposure to a higher dose of GnRHa facilitates in CC, and indirectly in the oocytes, the 
activation of those molecular pathways that lead to decrease cell damage and follicular apoptosis 
during chemotherapy. 
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Our data suggest that the protective gonadal effect of GnRHa treatment during chemotherapy 
with cyclophosphamide may be indirect and mediated through the surrounding CC. Despite this 
being a preliminary study, it adds knowledge on the potential mechanisms of action for the protective 
effects of GnRHa during chemotherapy, a therapeutic strategy that is now endorsed for clinical use 
by several guidelines. In order to overcome the intrinsic limitation of the presented study in terms of 
transcript/proteome coverage, future wide analyses could complement our results by larger depth 
investigations of the precise molecular mechanisms [56,57]. 
4. Materials and Methods  
4.1. COC Collection  
Human immature COC, retrieved for assisted reproduction and discarded because they were 
not suitable for in vitro fertilization, were collected from 111 women between March 2014 to March 
2017 by transvaginal oocyte aspiration 36 hours after injection of human chorionic gonadotropin. All 
COC derived from women < 38 years old (range: 22–38 years), with a normal ovarian reserve [58], 
without any ovarian pathology. A standard controlled ovarian stimulation protocol including 
gonadotropin administration in combination with GnRH antagonist was applied as previously 
described [59]. Under SZX7 stereomicroscope (Olympus Corporation, Tokyo, Japan), evaluation of 
COC maturity was based upon the expansion and radiance of the cumulus-corona complex, which 
surrounds the oocyte [60]. Absence of expanded cumulus-corona complex was associated with oocyte 
immaturity. Immature COC were incubated in Sydney IVF Fertilization medium (Cook Medical, 
Bloomington, IN, USA) at 37 °C in a humidified atmosphere of 6% CO2, 5% O2 using Galaxy 48R 
incubator (New Brunswick Scientific, Edison, NJ, USA). COC culture was performed in Nunc™ 4-
well IVF dishes (Thermo Fisher Scientific, Waltham, MA USA). 
4.2. Ethical Approval 
Human immature COC, not suitable for IVF treatment, were donated after written informed 
consent. The study was approved by the Ethics Committee of Regione Liguria (approval n. 
032REG2013, approved on November 12th, 2013). 
4.3. Study Design  
We treated whole COC and then analyzed the effect of GnRHa and cyclophosphamide in the 
oocyte and CC compartments, separately. The COC were randomly assigned to each treatment group 
using a computer-generated randomization list: i) Control group (no drugs) (C); ii) GnRHa-treated 
group (A); iii) Chemotherapy-treated group (P); iv) Chemotherapy plus GnRHa-treated group (A+P). 
A total of 260 COC were analyzed, we utilized 200 COC for gene expression analysis (five replicates 
of the four experimental groups, pools of 10 oocytes and relative CC), and 60 COC for protein analysis 
(three replicates of the four experimental groups, pools of 5 oocytes and relative CC).  
4.4. In Vitro Treatments   
The control group was incubated for 48 h in the Sydney IVF Fertilization medium. At t0 in group 
A the GnRHa (1 µM triptorelin, the concentration that obtain the maximum protection effect 
according to Imai et al. [31]; Sigma-Aldrich S.r.l., Milan, Italy) was added, and incubation was 
performed for 48 h. At t0 + 24 h in group P the chemotherapy (30 µM) was added and incubation was 
performed for 24 h. We chose the chemotherapy dose by performing preliminary MTT assay on 
cumulus cells. At t0 in group A+P the GnRHa (1 µM) was added, the incubation was performed for 
24 h, and then the chemotherapy (30 µM) was added for additional 24 h of incubation. Phosphamide 
mustard was used as a chemotherapy agent considering it is the active metabolite of 
cyclophosphamide (Open Chemical Repository, Developmental Therapeutics Program, National 
Institutes of Health,  Rockville, MD, USA).  
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4.5. RNA Isolation, Quantitation and Retro-transcription  
At the end of treatment, the oocytes were denuded of CC by enzymatic treatment with 80 IU/mL 
hyaluronidase solution (Origio, Målov, Denmark). Oocytes and CC were separately washed in 
Phosphate buffered saline (PBS), frozen in Qiazol (Qiagen, Hilden, Germany), and stored at −80 °C. 
Pools of 10 oocytes and CC were used for molecular analyses separately. Total RNA was extracted 
from each pool using the miRNeasy Micro kit (Qiagen), according to the manufacturer’s procedure. 
Quantification and quality control of total RNA were performed by RNA 6000 Pico kit on a 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). The RNA (2 ng or 10 ng for oocytes and 
CC, respectively) was amplified and reverse-transcribed using Ovation Pico WTA System V2 
(NuGEN, AC Leek, The Netherlands) following the manufacturer’s instructions. cDNA was purified 
by Mini Elute kit (Qiagen) and diluted 1:10 for molecular analyses. 
4.6. Quantitative PCR (qPCR) 
We investigated the following targets: i) GnRH receptor genes (GnRHR-I and GnRHR-II); ii) Pro-
apoptotic (BAX, BAK, BCL2L10, CD40, TRAF3, TP53, TP63, CASP3, TNF-α, FAS, FASL, and TRAIL) 
and anti-apoptotic (BCL2, BIRC5, CFLAR, BAG3, and TRAF2) genes; iii) Sphingomyelin pathway: 
sphingomyelin phosphodiesterase 1 (SMPD1), ceramide synthase 1 (CERS1), N-acylsphingosine 
amidohydrolase 1 (ASAH1), and sphingosine-1-kinase (SPHK1) genes; iv) glutamate-cysteine ligase 
(GCLM), the first rate limiting enzyme of glutathione synthesis. HPRT1 was used as reference gene. 
Specific TaqMan® assays were performed in triplicate in a Mastercycler epRealPlex2S system 
(Eppendorf, Hamburg, Germany). Negative control (water as template) was run simultaneously. 
4.7. Western Blot Analysis 
The CC were lysated in RIPA Buffer with 0.1 mM Phenylmethanesulfonyl fluoride (PMSF, Cell 
Signaling Technology Danvers, MA, USA) and protease inhibitors (Sigma S.r.l.). The lysates were 
stored at −20 °C. Protein amount was evaluated using Pierce™ 660 nm Protein Assay Reagent (Pierce 
Biotechnology, Rockford, IL, USA) and micro DC Protein Assay (Biorad Laboratories, Hercules, CA, 
USA). Proteins were resolved in 4–20% SDS Mini Protean TGX Precast gels (Biorad) and transferred 
on a PVDF membrane using a Trans-Blot Turbo Trasfert System (Biorad). Membranes were blocked 
with 1% no fat milk in PBS containing 0.05% Tween 20 for 1 h and probed with rabbit polyclonal anti-
BAX (Cell Signaling Technology) antibody overnight at +4 °C. Bound antibody was detected using 
horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (Cell Signaling 
Technology) incubated 1 h at room temperature. Proteins were detected by chemiluminescence 
(Clarity Western ECL Substrate, Biorad) using UVITEC Imaging System (Cleaver Scientific, 
Cambridge, UK). Quantification was performed after normalization on the β-actin band 
immunoassayed (HRP-conjugated β-Actin Rabbit monoclonal antibody, Cell Signaling Technology). 
4.8. Statistical Analysis 
RealPlex software v.2.0 (Eppendorf) was used to determine quantification cycle (Cq). Results of 
qPCR were expressed as relative values (ddCq method [61] using HPRT1 as reference gene [62]) and 
control group as calibrator). Mann-Whitney test (MedCalc® software, Mariakerke, Belgium) was used 
to test the significance of the difference between the sum of the ranks of each target gene measured 
in each treatment groups. Between treatment groups differences were considered statistically 
significant at a two-sided P-value < 0.05. 
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